bluuebunny/crossref_metadata_2025_split huggingface dataset:
CORRELATION BETWEEN VASCULAR INFLAMMATION MARKERS, DIASTOLIC DYSFUNCTION AND CARDIOVASCULAR RISK IN PATIENTS WITH TAKAYASU ARTERITIS
Authors: Cicco Sebastiano , Desantis Vanessa , Vacca Antonio , Cazzato Gerardo , Solimando Antonio G. , Susca Cecilia , Brosolo Gabriele , Caterna Cristiana , Lamanuzzi Aurelia , Saltarella Ilaria , Frassanito Maria Antonia , Ingravallo Giuseppe , Resta Leonardo , Ranieri Giuseppe , Montagnani Monica , Ria Roberto 
Published: June 2022

Objective:
Takayasu arteritis (TAK) increases vascular stiffness and arterial resistance. Abnormal immune response is a crucial factor in the pathogenesis of TAK. Here, we investigated I) vascular and cardiac ultrasonography parameters as increased cardiovascular risk in TAK patients, compared to atherosclerotic patients; ii) Treg and Th17 cells frequencyin TAK-refractory patients treated with infliximab

Design and method:
Clinical, instrumental and biochemical data in patients with active TAK were compared in a case control study were compared to age- and sex-matched atherosclerotic patients. In a subpopulation of TAK patients, Treg/Th17 cells percentage was measured before (T0) and after 18 months (T18) of infliximab treatment. Echocardiogram, supraaortic Doppler ultrasound, and lymphocytogram were carried out in all patients. Histological and immunohistochemical analysis were performed to correlate vessel wall patho-morphology and clinical/laboratory results

Results:
TAK patients displayed increased aortic valve dysfunction and diastolic dysfunction compared to atherosclerosis. Moderate-to-severe aortic regurgitation correlates with the highest serum levels of uric acid in TAK patients. A significant increase in aortic stiffness was associated with peripheral T lymphocyte levels. Increase in CD3+CD4+ and CD8+ infiltration and High-mobility group box 1 (HMGB1) was significantly higher in TAK group. CD15+ neutrophils were significantly higher in TAK, suggesting an association with inflammation-related vascular damage. Flow cytometric Tregs percentage was significantly reduced in TAK patients. Interestingly, in patients treated with infliximab, this value significantly increased at T18 compared to T0. Concomitantly, the frequency of CD3+CD4+IL-17+ cells behaved in the opposite way: the higher number of Th17 cells observed in TAK patients at T0 compared to controls significantly decreased at T18 compared to T0.
Supporting the specific pathogenetic mechanisms of vessel damage in TAK, we found an increased risk of cardiovascular disease that correlates directly with the degree of inflammatory cell infiltration in the vessel wall.

Conclusions:
These observations strengthen the clinical efficacy of infliximab in TAK patients, supporting the idea that biologic therapy may achieve a better control of TAK progression and help to stabilize the Treg/Th17 score toward values similar to those found in atherosclerotic patients
ANTIPLATELET AND ANTICOAGULANT THERAPY DURING ANGIOPLASTY PROCEDURES FOR ATHEROMATOUS OR FIBROMUSCULAR DYSPLASIA RENAL ARTERY STENOSIS: A SURVEY OF PRACTICES IN EUROPEAN SOCIETY OF HYPERTENSION EXCELLENCE CENTRES (ESH-EC) IN FRANCE
Authors: Bouhanick Beatrice , Amar Jacques , Amar Laurence , Courand Pierre Yves , Delsart Pascal , Denolle Thierry , Doublet Julien , Fauvel Jean Pierre , Fesler Pierre , Girerd Xavier , Jeune Sylvain Le , Pelletier Caroline , Rossignol Patrick , Rodière Mathieu , Silhol François , Lopez-Sublet Marilucy 
Published: June 2022

Objective:
Recommendations framing antiplatelet therapy (APT) and/or anticoagulation (AC) therapy during renal artery angioplasty procedures remain succinct or absent¹.
The aim was to describe the practice of using APT and AC in the 17 French ESH-EC during renal artery angioplasties for atheromatous stenoses (AS) or fibromuscular dysplasia stenoses (FMD).

Design and method:
Sending of a questionnaire via the French Society of Hypertension mailing to collect data with a reminder 1 month later.

Results:
Are summarized in the table. 12 centres responded partially or completely for AS and 10 for FMD. 2 centres considered that they did not recruit enough; 3 did not respond.

Conclusions:
In AS, single APT before angioplasty is the rule, while double APT is routine after angioplasty for 1 month, followed by single APT over the long term. In FMD, in most cases (90% of cases) there is no double APT before or after angioplasty (except in the case of dissection), while a single APT is continued in 60% of cases over the long term. Anticoagulants are reserved for bolus injection in operating room (with some exceptions) for both AS and FMD.
For AS, the handling of APT (duration, dose) differs, due to the lack of recommendations. In contrast, the use of AC/APT seems to be homogeneous in FMD before and during angioplasty, in accordance with the recommendations ¹.
¹Gornik HL et al. J Hypertens. 2019 Feb;37(2):229-252
URINARY ALBUMIN EXCRETION CHANGES AFTER ADRENALECTOMY IN PATIENTS WITH PRIMARY ALDOSTERONISM
Authors: Herrera Isabel Galceran , Closa Andres Ribas , González Susana Vázquez , Barrio Marta Crespo , Serrano Anna Oliveras 
Published: June 2022

Objective:
We aimed to evaluate changes in urinary albumin excretion (UAE) in patients with primary aldosteronism (PA) after adrenalectomy compared with those who remained with non-surgical treatment.

Design and method:
We evaluated 28 patients with PA diagnosed by adrenal venous sampling (AVS), attended by hypertension specialists or endocrinologists in Hospital del Mar, Barcelona. Office blood pressure (BP), body weight and laboratory parameters (estimated glomerular filtration rate by CKD-EPI equation (eGFR), plasma potassium (K) and UAE) were analyzed before and at 6 months after adrenalectomy (Adx group) or before and 6 months after AVS (non-Adx group).

Results:
Most patients (66.7%) were male and the mean age was 55.8 ± 9.6 years. Twelve patients (42.8%) underwent adrenalectomy and 16 (57.1%) remained on pharmacological treatment alone. Spironolactone was the principal antihypertensive treatment in the non-Adx group (84.6% of patients). The proportion of diabetes mellitus was similar in both groups (12.5% in Adx group vs 16.2% in non-Adx group, p = 0.6).
The decrease in BP was statistically significant in both groups (table 1). Adx group patients showed a statistically significant reduction in the UAE (-7.7 [-33.2 to -4.0] mg/g, p = 0.002) compared to patients in non-Adx group (+0.1 [-6.5 to + 24.9], p = 0.8).
After six months, the mean reduction in UAE (log-transformed) was significantly superior in the Adx group than in the non-Adx group. After adjusting by variation of systolic-BP and variation of body weight, a mean difference between the two groups of -0.966 mmHg (95% CI -1.746 to -1.182); p = 0.018 was observed.

Conclusions:
Patients with PA who underwent adrenalectomy presented a higher reduction in UAE than patients who remained on pharmacological treatment alone.
THE EFFECT OF RENAL DENERVATION ON THE CIRCADIAN BLOOD PRESSURE PATTERN IN PATIENTS WITH RESISTANT HYPERTENSION
Authors: Anna Moiseeva , Alexandru Caraus , Marcel Abras , Nicolae Ciobanu , Vitalie Moscalu , Artiom Surev , Maria Cociu , Mihaela Caraus , Alla Falkovskaya 
Published: June 2022

Objective:
Loss of the normal circadian rhythm of blood pressure is associated with adverse cardiovascular outcomes, the activity of the sympathetic nervous system in this context having an important pathophysiological mechanism. So, the objective of the study was to evaluate the impact of sympathetic renal denervation on circadian blood pressure pattern in patients with resistant hypertension.

Design and method:
The study included 75 patients with resistant hypertension, without comorbidities and mean age of 49.59 ± 0.52 years. After a 3 week standardized treatment with Losartan, Amlodipine and Indapamide patients were randomly assigned into three equal groups, depending on medication supplemented to the previously administered: I M group (n = 25) – Moxonidine, II B group (n = 25) - Bisoprolol and III D group (n = 25) – renal artery denervation. AMBP was done at baseline and 6 months follow-up. Renal denervation was performed using Medtronic Spyral catheters.

Results:
At baseline, most patients presented a non-dipper pathological profile for both systolic and diastolic blood pressure (Table 1).
At 6 months of evaluation, the improvement of the diurnal profile was recorded in all three observational groups, renal denervation demonstrating a net superior effect compared to the SNS-blockers. In this way, towards the end of the study the dipper profile for SBP was recorded in 5 (20%), 4 (16%) and 10 (40%) patients, non-dipper – in 19 (76%), 21 (84%) and 15 (60%) patients from I M, II B and III D groups, respectively; night-picker pattern was noted in 1 (4%) patient from I M group, over-dipper profile not being registered (p > 0.05, x2 = 6.28). Circadian DBP pattern noted the disappearance of pathological profiles night-picker and over-dipper, non-dipper being registered in 19 (76%), 18 (72%) and 16 (64%) patients, the physiological dipper profile was recovered by 6 (24%), 7 (28%) and 9 (36%) patients from I M, II B and III D groups, respectively (p > 0.05, x2 = 0.90).

Conclusions:
Renal denervation has shown efficacy in improving the circadian diurnal profile, thus reducing the risk of cardiovascular events in patients with resistant hypertension.
CENTRAL AND BRACHIAL PULSE PRESSURE PREDICTS CARDIOVASCULAR AND RENAL EVENTS IN TREATED HYPERTENSIVE PATIENTS
Authors: Takenaka Tsuneo 
Published: June 2022

Objective:
Central blood pressure is a stronger predictor of cardiovascular prognosis rather than brachial blood pressure. Reflection wave reaches abdominal aorta sooner than ascending aorta. Thus, the contribution of central pulse pressure (cPP) to renal events may differ from that to cardiovascular events.

Design and method:
The subanalysis of ABC-J II study (Hypertens Res. 2018;41:947–956) was performed. Subjects were 3434 treatedhypertensive patients with mean follow-up of 4.7 years. The contribution of brachial pulse pressure (bPP) and cPP to cardiovascular and renal events were analyzed.

Results:
Cox proportional-hazard analysis revealed that sex (p < 0.001), height (p < 0.05), history of cardiovascular diseases (p < 0.001), numbers of antihypertensive drugs (p < 0.05) and cPP (p < 0.05) contributed to cardiovascular events. However, baseline serum creatinine (p < 0.001) and bPP (p < 0.05) were selected as significant predictors of renal events.

Conclusions:
The present findings indicate that cPP and bPP independently contribute to cardiovascular and renal events, and suggest that the diverse results may be attributable to the anatomy that abdominal aorta feeds renal arteries, but thoracic aorta does cerebral and coronary arteries.
ALDOSTERONE SYNTHASE CYP11B2 (-344C/T) GENE POLYMORPHISM INFLUENCES RISK OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH ARTERIAL HYPERTENSION
Authors: Dzhuryak Valentyna , Sydorchuk Andrii , Voroniuk Ksenia , Sydorchuk Larysa , Repchuk Yulia , Semianiv Marianna , Sydorchuk Ruslan , Sydorchuk Iryna , Iftoda Oksana 
Published: June 2022

Objective:
Renin-angiotensin aldosterone system plays a major role in blood pressure regulation. Aldosterone, synthesized in the adrenal cortex by aldosterone synthase is encoded by the cytochrome 11B2 aldosterone synthase gene (CYP11B2). The aim of the study was to analyze the association of aldosterone synthase gene (CYP11B2) biallelic polymorphism (-344C/T) with Chronic Kidney Disease (CKD) in patients with essential arterial hypertension (EAH) in West-Ukrainian population.

Design and method:
One-hundred subjects with EAH and target-organ damaging (2nd stage), moderate, high or very high cardiovascular risk were involved in the case-control study. Among them 79.0% (79) females and 21.0% (21) males, mean age 59.87 ± 8.02 yo; disease duration from 6 to 25 years. CKD was determined by the National Kidney Foundation recommendations (Kidney Disease: Improving Global Outcomes (KDIGO), 2012) after glomerular filtration rate (GFR) decline < 60 ml/min/1.73sq.m for over 3 months (by Cockroft-Gault formula and CKD-EPI for Cystatin-C and Creatinine serum levels depending on gender). CKD was diagnosed in 29 persons. All enrolled / screened patients signed the Informed Consent to participate in the research. Control group included 48 practically healthy persons of relevant age. Gene polymorphism of aldosterone synthase gene CYP11B2 (-344C/T) was examined by polymerase chain reaction (PCR).

Results:
The probability of EAH in observed population increased 1.49 times in T-allele carriers of CYP11B2 gene, but only in females [OR = 1.90; 95%CI:1.02–3.54; p = 0.029], with contrary decreasing in C-allele women (p = 0.041). No relevant dependences were observed in hypertensive males. Also T-allele increased probability of CKD (GFR< 60 ml/min/1,73m2) in hypertensive population 1.48 times [OR = 1.86; 95%CI:1.01–3.58; p = 0.049], especially in T-allele females 1.53 times [OR = 6.51; 95%CI:1.39–30.60; p = 0.007] with low CKD risk in T-allele males [OR = 0.15; 95%CI:0.03–0.72; p = 0.009], respectively. Some predictors like DM2, the 2nd and 3rd grades of Obesity, and the 3rd grade level of Blood Pressure elevation escalated the risk of CKD 2.4, 2.08–2.32 and 2.91 times, accordingly (p< 0.05).

Conclusions:
Aldosterone synthase gene CYP11B2 (-344C/T) is associated with EAH. T-allele increased risk of CKD in hypertensive population, especially in females.
HIGH INCIDENCE OF CHRONIC KIDNEY DISEASE IN THE BELARUSIAN POPULATION PARTICULARLY IN PATIENTS WITH ARTERIAL HYPERTENSION
Authors: Schastlivenko Andrei , Vykhrystenka Ludmila 
Published: June 2022

Objective:
To study the true incidence of chronic kidney disease in Vitebsk urban unorganized population (Belarus).

Design and method:
During research the representative group consisting of 315 persons from Vitebsk urban unorganized population was formed. The survey included standard questionnaires (WHO) for detection of cardiovascular risk factors, measurements of blood pressure, electrocardiography, kidney ultrasound and serum creatinine values. Chronic kidney disease is defined as abnormalities of kidney structure or function, present for 3 months, with implications for health (KDIGO, 2012).
For diagnosis of arterial hypertension have been used according to guidelines on blood pressure management in chronic kidney disease (2021).

Results:
The average age of the population in the representative sample was 47.3 + -0.7 years. The prevalence of chronic kidney disease in the representative sample was 22.9%. The frequency of incidence of arterial hypertension in the representative sample was 33.3%. The prevalence of chronic kidney disease among patients with arterial hypertension was 42.9%. Thus, a higher incidence of chronic kidney disease was found in patients with arterial hypertension (42.9%) compared to the unorganized population (22.9%) (df = 1; x2 = 6.4; p < 0.01).

Conclusions:
High prevalence of chronic kidney disease is becoming a health problem in people of Belarus particularly in patients with arterial hypertension.
EFFECT OF CHRONIC KIDNEY DISEASE ON PROGNOSIS OF PATIENTS WITH ACUTE CORONARY SYNDROME
Authors: Gkini Konstantia-Paras , Terentes-Printzios Dimitrios , Aznaouridis Konstantinos , Georgakopoulos Christos , Gardikioti Vasiliki , Kallikazaros Ioannis , Tsioufis Konstantinos , Vlachopoulos Charalambos 
Published: June 2022

Objective:
Chronic kidney disease (CKD) is associated with worse prognosis in acute coronary syndromes (ACS).
We sought to investigate the prognostic effect of conservative management of ACS in CKD patients in a tertiary University Hospital.

Design and method:
Two hundred and one patients (mean age 66.5 ± 13.6 years, 150 males) admitted to our Hospital with ACS from 2016–2017 were included in the study. CKD was defined by an estimated glomerular filtration rate (eGFR) < 60 ml/min/m2, as assessed by the Modification of Diet in Renal Disease (MDRD) equation. We grouped patients into four groups according to their CKD status and whether they underwent coronary angiography or not. Patients were followed for a median of 2 years post the index event. The primary outcome was all-cause death and secondary outcomes were cardiovascular and non-cardiovascular death.

Results:
The majority of patients (n = 120, 60%) presented with non-ST elevation ACS (NSTE-ACS), whereas 81 patients as ST-elevation myocardial infarction (STEMI) (40%). 135 patients (68%) had history of hypertension. Fifty-four patients (27%) were identified as CKD patients. Overall, 29 patients (14.4%) did not undergo coronary angiography. Patients at a higher age and with CKD were more likely to not undergo angiography. Thirty-seven (18.4%) died during follow-up (25 non-cardiovascular deaths and 12 cardiovascular deaths). Patients with conservative treatment and CKD had the worse prognosis (Hazard ratio [HR] = 11.00, 95% Confidence intervals [CI] 4.00 to 30.24, p < 0.001) followed by non-CKD patients with conservative treatment (HR = 4.37, 95% CI 1.20 to 15.90, p = 0.025) compared to non-CKD patients treated invasively (reference group) after adjusting for age, gender, STEMI/NSTE-ACS diagnosis. Results were similar for non-cardiovascular death, whereas regarding cardiovascular death only the group with CKD and conservative treatment had a lower survival compared to the reference group (HR = 26.5, 95% CI 2.9 to 241.7, p = 0.004)

Conclusions:
Patients with ACS and CKD have higher mortality from both cardiovascular and non-cardiovascular causes than patients without CKD. Regardless of CKD status, conservative management of ACS was associated with higher long-term mortality versus invasive management in all patients.
IMPACT OF THE CARDIOVASCULAR POLYPILL (TRINOMIA) ON CHRONIC KIDNEY DISEASE. PROSPECTIVE REAL-LIFE DATA
Authors: Cuadrado-Payán Elena , Rodríguez-Espinosa Diana , Casals-Urquiza Joaquim , Risco-Zevallos Jimena Del , Hermida Evelyn , López-Romero Luis Carlos , Rodas Lida , Broseta Jose Jesús 
Published: June 2022

Objective:
Cardiovascular diseases are the leading cause of mortality and morbidity worldwide. Moreover, chronic kidney disease (CKD) patients exhibit significantly higher incidence and prevalence of cardiovascular events. In this population, used to a high burden of pills, the importance of a polypill-based treatment strategy increases to simplify treatment and ensure adherence.
The cardiovascular polypill composition includes a lipid-lowering drug, antihypertensive agent, and antiplatelet therapy and is marketed in Spain since 2015 with the name of Trinomia.
This report aims to obtain real-life data to evaluate ifTrinomia improves the standard of care.

Design and method:
Prospective, single-center, observational study of a cohort of CKD patients under the standard of care starting any combination of Trinomia in secondary prevention. Patient demographics, clinical history, blood pressure, and analysis of blood lipids, albumin-to-creatinineratio, and estimated glomerular filtration rate were measured at baseline and 6 and 12 months after starting treatment

Results:
A total of 49 patients (35 males) were included, with a mean age of 78,83 years (range 51–95). 91,83% had hypertension, 63,26% with type 2 diabetes and 2,04% with type 1 diabetes. Regarding the cause of secondary prevention, 75,4% had cardiovascular disease, 16,4% had a stroke, and 8.16% had both. All laboratory results are displayed in table 1.

Conclusions:
Although most of the variables studied, probably because it was a small group of patients with adequate baseline control, did not reach statistical significance, some results are worth noting. eGFR is 3 points higher at one year, with a reduction in UACR, which does not reach statistical significance but translates into a lower hyperfiltration without worsening renal function or an increase in serum potassium. In addition, there was a 5-point decrease in systolic blood pressure and a 3-point in diastolic (n.s.), and a better lipid profile is achieved, with a 10-point reduction in LDL and a 24-point reduction in triglycerides.
COMPARISON OF AMBULATORY CENTRAL HEMODYNAMICS AND ARTERIAL STIFFNESS IN HEMODIALYSIS PATIENTS WITH AND WITHOUT INTRADIALYTIC HYPERTENSION
Authors: Theodorakopoulou Marieta , Alexandrou Maria-Eleni , Iatridi Fotini , Faitatzidou Danai , Karpetas Antonios , Bikos Athanasios , Papagianni Aikaterini , Sarafidis Pantelis 
Published: June 2022

Objective:
Increased arterial stiffness is suggested to be involved in the pathogenesis of intradialytic hypertension (IDH). Ambulatory pulse wave velocity (PWV) is an independent predictor for all-cause-mortality in hemodialysis patients and its prognostic power is better than office PWV. This is the first study comparing ambulatory central blood pressure (BP) and arterial stiffness parameters between patients with and without IDH.

Design and method:
This study examined 45 patients with IDH (defined as: SBP rise greater than or equal to 10 mmHg from pre- to post-dialysis and post-dialysis SBP greater than or equal to 150 mmHg) in comparison 197 without IDH. All participants underwent 48-h ABPM with the Mobil-O-Graph-NG device; parameters of central hemodynamics [central systolic (cSBP) and diastolic BP (cDBP), pulse pressure (PP)], wave reflection [augmentation index (AIx), and pressure (AP)] and PWV were estimated.

Results:
Age, dialysis vintage, interdialytic weight gain and prevalence of major comorbidities did not differ between the two study groups. Patients with IDH had higher 44-h cSBP (131.6 ± 16.7 vs. 119.3 ± 15.6, p < 0.001), 44-h cDBP (86.4 ± 12.8 vs. 79.3 ± 11.7, p < 0.001) and 44-h cPP (45.7 ± 10.7 vs. 40.3 ± 10.3, p = 0.002) levels compared to patients without IDH. Similarly, during day- and nighttime periods, cSBP/cDBP and cPP levels were higher in IDH patients compared to non-IDH. 44-h augmentation pressure and index, but not AIx(75) were higher in patients with IDH than those without IDH. 44-h PWV (10.0 ± 2.0 vs. 9.2 ± 2.1 m/s, p = 0.020) was significantly higher in patients with IDH.

Conclusions:
Patients with IDH have higher ambulatory central BP and increased arterial stiffness, as indicated by higher ambulatory cPP and PWV. Increased arterial stiffness could be a prominent factor associated with the high burden of cardiovascular disease in this population.